Posaconazole: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Background == |
|||
==Therapeutic Drug Monitoring== |
|||
* Azole antifungal |
|||
*Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption |
|||
*For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy |
|||
=== Pharmacokinetics and Pharmacodynamics === |
|||
*For treatment, target trough >1 mg/L |
|||
* Generally distributes well, with the notable exception of non-inflamed brain |
|||
===Clinical Breakpoints=== |
===Clinical Breakpoints=== |
||
| Line 10: | Line 12: | ||
! rowspan="2" |ECV (μg/mL) |
! rowspan="2" |ECV (μg/mL) |
||
! colspan="4" |Breakpoints (μg/mL) |
! colspan="4" |Breakpoints (μg/mL) |
||
! colspan="4" |Breakpoints (mm) |
|||
|- |
|- |
||
!S |
!S |
||
!SDD |
|||
!I |
!I |
||
!R |
|||
!S |
|||
!SDD |
!SDD |
||
!I |
|||
!R |
!R |
||
|- |
|- |
||
| Line 24: | Line 21: | ||
|0.06 |
|0.06 |
||
|≤0.06 |
|≤0.06 |
||
| colspan="2" rowspan="9" | |
|||
| |
|||
| |
|||
|≥0.12 |
|≥0.12 |
||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida dubliniensis]] |
|[[Candida dubliniensis]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 45: | Line 31: | ||
|[[Candida glabrata]] |
|[[Candida glabrata]] |
||
|2 |
|2 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 56: | Line 36: | ||
|[[Candida guilliermondii]] |
|[[Candida guilliermondii]] |
||
|0.5 |
|0.5 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 67: | Line 41: | ||
|[[Candida kefyr]] |
|[[Candida kefyr]] |
||
|0.25 |
|0.25 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 78: | Line 46: | ||
|[[Candida krusei]] |
|[[Candida krusei]] |
||
|0.5 |
|0.5 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 89: | Line 51: | ||
|[[Candida lusitaniae]] |
|[[Candida lusitaniae]] |
||
|0.12 |
|0.12 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 101: | Line 57: | ||
|0.25 |
|0.25 |
||
|≤0.06 |
|≤0.06 |
||
| |
|||
| |
|||
|≥0.12 |
|≥0.12 |
||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida tropicalis]] |
|[[Candida tropicalis]] |
||
|0.12 |
|0.12 |
||
|≤0.06 |
|≤0.06 |
||
| |
|||
| |
|||
|≥0.12 |
|≥0.12 |
||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Cryptococcus neoformans]] |
|[[Cryptococcus neoformans]] |
||
| |
| |
||
| colspan=" |
| colspan="4" rowspan="2" | |
||
|- |
|- |
||
|[[Cryptococcus gattii]] |
|[[Cryptococcus gattii]] |
||
| |
| |
||
|- |
|||
|[[Aspergillus flavus]] |
|||
|0.5 |
|||
|— |
|||
| colspan="2" rowspan="5" | |
|||
|— |
|||
|- |
|||
|[[Aspergillus fumigatus]] |
|||
|0.25 |
|||
|≤0.125 |
|||
|>0.25 |
|||
|- |
|||
|[[Aspergillus nidulans]] |
|||
|0.5 |
|||
|— |
|||
|— |
|||
|- |
|||
|[[Aspergillus niger]] |
|||
|0.5 |
|||
|— |
|||
|— |
|||
|- |
|||
|[[Aspergillus terreus]] |
|||
|0.25 |
|||
|≤0.125 |
|||
|>0.25 |
|||
|} |
|} |
||
== Dosing == |
|||
=== Therapeutic Drug Monitoring === |
|||
*Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption |
|||
*For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy |
|||
*For treatment, target trough >1 mg/L |
|||
*In Ontario, it may be available through [https://www.chusj.org/labotest/accueil CHU Saine-Justine] in Quebec ([https://chusj.omni-assistant.net/labo/AnalysisRegistry/AnalysisView.aspx?PK_Analysis=446 link to LTIG entry]) |
|||
== Safety == |
|||
=== Adverse Events === |
|||
* Liver toxicity |
|||
** Generally transient and asymptomatic and self-limited |
|||
** See also [https://www.ncbi.nlm.nih.gov/books/NBK548934/ LiverTox] |
|||
[[Category:Triazoles]] |
[[Category:Triazoles]] |
||
Latest revision as of 15:00, 22 October 2024
Background
- Azole antifungal
Pharmacokinetics and Pharmacodynamics
- Generally distributes well, with the notable exception of non-inflamed brain
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | |||
|---|---|---|---|---|---|
| S | I | SDD | R | ||
| Candida albicans | 0.06 | ≤0.06 | ≥0.12 | ||
| Candida dubliniensis | |||||
| Candida glabrata | 2 | ||||
| Candida guilliermondii | 0.5 | ||||
| Candida kefyr | 0.25 | ||||
| Candida krusei | 0.5 | ||||
| Candida lusitaniae | 0.12 | ||||
| Candida parapsilosis | 0.25 | ≤0.06 | ≥0.12 | ||
| Candida tropicalis | 0.12 | ≤0.06 | ≥0.12 | ||
| Cryptococcus neoformans | |||||
| Cryptococcus gattii | |||||
| Aspergillus flavus | 0.5 | — | — | ||
| Aspergillus fumigatus | 0.25 | ≤0.125 | >0.25 | ||
| Aspergillus nidulans | 0.5 | — | — | ||
| Aspergillus niger | 0.5 | — | — | ||
| Aspergillus terreus | 0.25 | ≤0.125 | >0.25 | ||
Dosing
Therapeutic Drug Monitoring
- Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
- For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
- For treatment, target trough >1 mg/L
- In Ontario, it may be available through CHU Saine-Justine in Quebec (link to LTIG entry)
Safety
Adverse Events
- Liver toxicity
- Generally transient and asymptomatic and self-limited
- See also LiverTox
